These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12802033)

  • 61. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design.
    Behera M; Kumar A; Soares HP; Sokol L; Djulbegovic B
    Cancer Control; 2007 Apr; 14(2):160-6. PubMed ID: 17387301
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
    Bogaerts J; Sydes MR; Keat N; McConnell A; Benson A; Ho A; Roth A; Fortpied C; Eng C; Peckitt C; Coens C; Pettaway C; Arnold D; Hall E; Marshall E; Sclafani F; Hatcher H; Earl H; Ray-Coquard I; Paul J; Blay JY; Whelan J; Panageas K; Wheatley K; Harrington K; Licitra L; Billingham L; Hensley M; McCabe M; Patel PM; Carvajal R; Wilson R; Glynne-Jones R; McWilliams R; Leyvraz S; Rao S; Nicholson S; Filiaci V; Negrouk A; Lacombe D; Dupont E; Pauporté I; Welch JJ; Law K; Trimble T; Seymour M
    Eur J Cancer; 2015 Feb; 51(3):271-81. PubMed ID: 25542058
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Challenges in the Design and Interpretation of Noninferiority Trials.
    Mauri L; D'Agostino RB
    N Engl J Med; 2017 Oct; 377(14):1357-1367. PubMed ID: 28976859
    [No Abstract]   [Full Text] [Related]  

  • 64. Rifampin in chronic granulomatous disease.
    Lorber B
    N Engl J Med; 1980 Jul; 303(2):111. PubMed ID: 7383064
    [No Abstract]   [Full Text] [Related]  

  • 65. [Orphan diseases: evaluations of new treatments].
    Bergmann JF; Delcey V; Champion K
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S202-5. PubMed ID: 18228689
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The review process fails to require appropriate statistical analysis of a group-randomized trial.
    Hannan PJ; French SA; Himes JH; Fulkerson JA; Story M
    Pediatrics; 2004 Aug; 114(2):509-11. PubMed ID: 15286244
    [No Abstract]   [Full Text] [Related]  

  • 67. Providing guidance in the dark: rare renal diseases and the challenge to improve the quality of evidence.
    Bolignano D; Nagler EV; Van Biesen W; Zoccali C
    Nephrol Dial Transplant; 2014 Sep; 29(9):1628-32. PubMed ID: 24026240
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Should clinical trials be approached differently for rare cancers?
    Olver I
    Future Oncol; 2016 May; 12(10):1207-9. PubMed ID: 26939845
    [No Abstract]   [Full Text] [Related]  

  • 69. A testing procedure for survival data with few responders.
    Freidlin B; Korn EL
    Stat Med; 2002 Jan; 21(1):65-78. PubMed ID: 11782051
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The propensity score, an increasingly applied statistical tool in cardiovascular research].
    Dimagli A; Di Mauro M; Benedetto U
    G Ital Cardiol (Rome); 2020 Oct; 21(10):760-763. PubMed ID: 32968311
    [No Abstract]   [Full Text] [Related]  

  • 71. [Why does knowledge on rare diseases allow progress in treatments?].
    Argiroffo CB; Superti-Furga A
    Rev Med Suisse; 2012 Feb; 8(329):395-6. PubMed ID: 22432238
    [No Abstract]   [Full Text] [Related]  

  • 72. Corticosteroids for chronic granulomatous disease.
    Quie PG; Belani KK
    J Pediatr; 1987 Sep; 111(3):393-4. PubMed ID: 3625407
    [No Abstract]   [Full Text] [Related]  

  • 73. Documenting rare disease data in China.
    Lin H; Long E; Chen W; Liu Y
    Science; 2015 Sep; 349(6252):1064. PubMed ID: 26339020
    [No Abstract]   [Full Text] [Related]  

  • 74. Amantadine in chronic granulomatous disease.
    Warner JO
    Lancet; 1985 Aug; 2(8452):447. PubMed ID: 2863473
    [No Abstract]   [Full Text] [Related]  

  • 75. Confronting complexity in the design and conduct of high-risk rare disease clinical trials.
    Stedman HH
    Mol Ther; 2023 May; 31(5):1191-1192. PubMed ID: 37141855
    [No Abstract]   [Full Text] [Related]  

  • 76. Room for improvement in clinical trials for rare diseases.
    Musters A; Tas SW
    Nat Rev Rheumatol; 2020 Mar; 16(3):131-132. PubMed ID: 31996788
    [No Abstract]   [Full Text] [Related]  

  • 77. The challenges of clinical trials in rare diseases.
    Mellerio JE
    Br J Dermatol; 2022 Oct; 187(4):453-454. PubMed ID: 36192346
    [No Abstract]   [Full Text] [Related]  

  • 78. Strategy for translational research and breakthroughs for common human diseases using excellent animal models and rare human diseases.
    Nakao K
    Endocr J; 2009; 56(5):637-8. PubMed ID: 19706992
    [No Abstract]   [Full Text] [Related]  

  • 79. The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens.
    Dane A; Rex JH; Newell P; Stallard N
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac266. PubMed ID: 35854983
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
    Blonda A; Barcina Lacosta T; Toumi M; Simoens S
    Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.